Genmab — Maj 2014
-
forventer stadig 4 fase III read outs på ofa i år
-
novod spørger til novartis
-
early next month launch arzerra first line
-
gsk-novartis - stadig ungt, gsk reassures business as usual, 4-6 months readouts scheduled
-
potential readout på gilead idelasilib i år
-
jan siger at arzerra gør det bedst af alle cd20
-
i kombi med de to small molecules
-
surprisesurprise - jan very excited to be working with powerhouse novatis
-
jan particularly excited - GSK very / firmly
committed to autoimmune!!!!! -
novatis deal vil close i H1 2015
-
novartis deal er en 3-part deal, hvor hver del er afhængig af de andre 2
-
ingen må falde igennem - ellers falder hele deal igennem
-
dlbcl readout coming in the not too distant future
-
lyder ikke som om GEN har haft ret meget kontakt med Novartis - det er stadig GSK, der skal køre den ind med penis
-
relaunch - fully on schedule. jan begejstret for materialet. immediatly after asco
-
no of iss studies to be presented
-
for GEN investors asco will be a FAR MORE important event for dara
-
incredibly important for dara!!!!!!!
-
head to head firs
-
maintenance read out summer early fall
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind